ଟେଟ୍ରାବେନାଜାଇନ

ଟେଟ୍ରାବେନାଜାଇନ
Clinical data
Trade names	Xenazine, Xentra, Nitoman, others
Synonyms	Ro-1-9569
AHFS/Drugs.com	Consumer Drug Information
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	Low, extensive first pass effect
Protein binding	82–85%
Metabolism	Liver (CYP2D6-mediated)
Elimination half-life	10 hours parent compound (2 to 8 hours active metabolites)
Excretion	Kidney (~75%) and fecal (7–16%)
Identifiers
	IUPAC name (SS,RR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one;
ECHA InfoCard	100.000.348
Chemical and physical data
Formula	C19H27NO3
Molar mass	୩୧୭.୪୩ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3C(CC(C)C)CN2C(c1c(cc(OC)c(OC)c1)CC2)C3;
	InChI InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3 ; Key:MKJIEFSOBYUXJB-UHFFFAOYSA-N ;
(verify)

ଟେଟ୍ରାବେନାଜାଇନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଜେନାଜାଇନ,ହେଉଛି ଏକ ଔଷଧ ଯାହା ହଣ୍ଟିଙ୍ଗଟନ କୋରିଆ ଏବଂ ଟାର୍ଡିଭ ଡିସକାଇନେସିଆ ସମେତ କେତେକ ଚଳପ୍ରଚଳ ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରାଳୁ ଭାବ, ଅବସାଦ, ବିରକ୍ତି ଭାବ, ଖରାପ ସମନ୍ୱୟ, ଅଇ, ଏବଂ ପତନ ହୋଇପାରେ ।^[୩] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉଚ୍ଚ ପ୍ରୋଲାକ୍ଟିନ୍, ନିମ୍ନ ରକ୍ତଚାପ, କ୍ୟୁଟି ବିସ୍ତାର, ନ୍ୟୁରୋଲେପ୍ଟିକ୍ ମାଲିଗନାଣ୍ଟ ସିଣ୍ଡ୍ରୋମ ଏବଂ ଗିଳିବାରେ ଅସୁବିଧା ହୋଇପାରେ ।^[୩] ଏହା ଏକ ଭେସିକୁଲାର ମୋନୋଆମିନ ପରିବହନକାରୀ ୨ ଇନହିବିଟର ।^[୩]

୨୦୦୮ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଟେଟ୍ରାବେନାଜାଇନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୫ ମିଗ୍ରା ବିଶିଷ୍ଟ ୧୧୨ବଟିକାର ମୂଲ୍ୟ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୧୦୦ ପାଉଣ୍ଡ ଥଲା ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧,୫୦୦ ଡଲାର ଅଟେ ।^[୫]

ଆଧାର[ସମ୍ପାଦନା]

↑ Yero, T.; Rey, J. A. (2008). "Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease". P & T: A Peer-Reviewed Journal for Formulary Management. 33 (12): 690–694. PMC 2730806. PMID 19750050.
↑ "Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015" (PDF). H. Lundbeck A/S. Archived (PDF) from the original on 31 July 2018. Retrieved 9 December 2015.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Tetrabenazine". drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2021. Retrieved 1 October 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 425. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Tetrabenazine Generic Xenazine". Retrieved 1 October 2021.

[hl-1] Yero, T.; Rey, J. A. (2008). "Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease". P & T: A Peer-Reviewed Journal for Formulary Management. 33 (12): 690–694. PMC 2730806. PMID 19750050.

[PI-2] "Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015" (PDF). H. Lundbeck A/S. Archived (PDF) from the original on 31 July 2018. Retrieved 9 December 2015.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Tetrabenazine". drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2021. Retrieved 1 October 2021.

[BNF80-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 425. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[5] "Tetrabenazine Generic Xenazine". Retrieved 1 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]